Estimating Quality-Adjusted Life-Year Loss Due to Noncommunicable Diseases in Korean Adults through to the Year 2040  by Ock, Minsu et al.
Avai lable onl ine at www.sc iencedirect .comV A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 1 – 6 61098-3015$36.00 – s
Outcomes Research
http://dx.doi.org/10
E-mail: mdjomin
* Address corres
Asanbyeongwon-giljournal homepage: www.elsevier .com/ locate / jva lEstimating Quality-Adjusted Life-Year Loss Due to
Noncommunicable Diseases in Korean Adults through to the
Year 2040
Minsu Ock, MD, MPA1, Jung Won Han, MS2, Jin Yong Lee, MD, PhD, MHA3, Seon-Ha Kim, RN, PhD4,
Min-Woo Jo, MD, PhD1,*
1Department of Preventive Medicine, University of Ulsan, Seoul, South Korea; 2University of Ulsan College of Medicine, Seoul, South
Korea; 3Public Health Medical Service, Seoul National University, Boramae Medical Center, Seoul, South Korea; 4Department of
Nursing, College of Health Science, Dankook University, Cheonan, South KoreaA B S T R A C TObjectives: To estimate the loss in quality-adjusted life-years (QALYs)
in Korean adults due to 13 noncommunicable diseases (NCDs) in 2010
and predict changes in QALY loss through to the year 2040. Methods:
Thirteen NCDs (hypertension, diabetes mellitus, hyperlipidemia,
stroke, myocardial infarction, angina, arthritis, osteoporosis, asthma,
allergic rhinitis, atopic dermatitis, cataract, and depression) were
selected from the Korean Community Health Survey 2010. The Euro-
Qol ﬁve-dimensional questionnaire index from the Korean Commun-
ity Health Survey 2010 and the Korean valuation set were used to
estimate utility weights according to sex, age, and disease. Morbidity
data were also obtained from the Korean Community Health Survey
2010. Mortality data according to disease and life expectancy were
retrieved from the Korean Statistical Information Service. To predict
future QALY loss, future population projection data from the Korean
Statistical Information Service were used as substitutes for 2010
population size. Results: Among the assessed 13 NCDs, the largestee front matter & 2015 Published by Elsevier Inc.
(ISPOR).
.1016/j.jval.2014.09.008
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pondence to: Min-Woo Jo, Department of Preve
, Songpa-Gu, Seoul 138-736, South Korea.total QALY loss was for hypertension (513,113 QALYs; units are
omitted hereafter), followed by arthritis (509,317) and stroke
(431,049). The largest QALY loss due to mortality was stroke
(306,733), whereas the largest QALY loss due to morbidity was arthritis
(502,513). By applying the middle estimate of future population, the
largest increase in total QALY loss between 2010 and 2040 was for
hypertension (840,582), followed by stroke (719,076) and diabetes
mellitus (474,607). Conclusions: Hypertension, arthritis, and stroke
are important in terms of total QALY loss, which will continuous to
increase because of aging. These results could be used to develop
cost-effective interventions that reduce the burden of NCDs.
Keywords: chronic disease, health-related quality of life,
noncommunicable diseases, quality-adjusted life-year.
& 2015 Published by Elsevier Inc. on behalf of International Society for
Pharmacoeconomics and Outcomes Research (ISPOR).Introduction
Although communicable diseases remain a global public health
concern, the global disease proﬁle has shifted from communi-
cable diseases to noncommunicable diseases (NCDs), such as
ischemic heart disease, cancer, and stroke [1]. NCDs have been
problematic in developed countries, but they are now global
pandemics with considerable effects in developing countries [2].
In 2010, NCDs accounted for 65% of total global deaths [3] and
mortality due to NCDs is expected to continue to increase
because of population growth and aging.
Measuring disease burden is the ﬁrst step toward establishing
health service and research priorities for NCDs [4]. There are
various methods for measuring disease burden, from epidemio-
logic indicators (such as mortality) to summary measures that
reﬂect both quantity and quality of life such as quality-adjustedlife-year (QALY), quality-adjusted life expectancy (QALE), or
disability-adjusted life-year (DALY) [5,6]. Among these, QALY
can integrate the impact of disease on mortality and morbidity
into a single index, thereby allowing comparisons between
different disease areas [5]. Similar to life expectancy, QALY can
be differently expressed using QALE, which is the total QALYs
throughout the remainder of the expected life at a certain age [7].
The National Institute for Health and Clinical Excellence of the
United Kingdom uses QALY as a tool to determine whether the
National Health Service should fund certain treatments [8]. In
addition, several studies use QALY to investigate the burden of
NCDs, such as stroke [9], diabetes [10], and cancer [11]. These
studies, however, focus on the QALYs of particular diseases. For
that reason, there is a certain limit for comparing the burden of
NCDs in terms of QALYs. Annual QALY loss was estimated for 29
chronic conditions, but only due to morbidity [12]. Althoughon behalf of International Society for Pharmacoeconomics and
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were calculated [13], in the future measuring and predicting
QALY loss for various NCDs will be needed to establish health
service and research priorities.
This study calculated QALY loss in Korean adults due to 13
NCDs. Furthermore, future changes in QALY loss were predicted
according to predicted changes in the population structure
of Korea.Methods
Data
We used data from the Korean Community Health Survey
(KCHS) 2010, which is the largest cross-sectional health survey
of the representative adult population (Z19 years old) of 253
regions in Korea [14]. A total of 229,229 people participated in
the KCHS 2010, and the survey was conducted using computer-
assisted personal interviews. The KCHS collected various
health-related data, including self-reported morbidity (15 dis-
eases), EuroQol ﬁve-dimensional questionnaire (EQ-5D), and
EuroQol visual analogue scale. After excluding tuberculosis
and hepatitis B viral infection, 13 diseases—hypertension, dia-
betes mellitus, hyperlipidemia, stroke, myocardial infarction,
angina, arthritis, osteoporosis, asthma, allergic rhinitis, atopic
dermatitis, cataract, and depression—were considered NCDs in
this study.
To estimate utility weights by sex and age group, the EQ-5D
index from the KCHS was used in conjunction with the Korean
EQ-5D valuation set [15]. A control group was needed to
conﬁrm the decrease in health-related quality of life (HRQOL)
in certain disease groups, and this decrease can be deter-
mined by comparisons with healthy or general population
controls. In this study, we used healthy controls as the
reference group, which were deﬁned as persons with no self-
reported morbidity and EQ-VAS scores of 70 or more according
to the KCHS 2010.
Mortality data were obtained from the Korean Statistical
Information Service from Statistic Korea. International Statistical
Classiﬁcation of Diseases, 10th Revision codes were used to link
morbidity and mortality. Table 1 presents 13 NCDs from the KCHS
2010 and their related International Statistical Classiﬁcation of Dis-
eases, 10th Revision codes. In addition, the population of Korea, life
expectancy, and the future population projection were obtained
from the Korean Statistical Information Service.Table 1 – The 13 noncommunicable diseases
assessed in this study and their ICD-10 codes.
Disease ICD-10 codes
Hypertension I10–I13
Diabetes mellitus E10–E14
Hyperlipidemia E780–E789
Stroke I60–I69
Myocardial infarction I21–I25
Angina I20
Arthritis M000–M259
Osteoporosis M80–M81
Asthma J45–J46
Allergic rhinitis J301–J304
Atopic dermatitis L200, L208, L209
Cataract H250–H269
Depression F320–F329
ICD-10, International Statistical Classiﬁcation of Diseases, 10th Revision.Calculating QALY Loss
Total QALY loss due to a speciﬁc disease is the sum of QALY
losses due to morbidity and mortality (Equation 1):
QALY losstotal¼QALY lossmorbidityþQALY lossmorbidity ð1Þ
QALY loss due to morbidity is equal to the sum of the individual
QALY losses due to morbidity and can be regarded as the differ-
ence in utility weights between healthy controls and diseased
people (Equation 2).
QALY lossmorbidity¼ ∑
2
s¼1
∑
13
n¼1
Ps,n Morbs,n  UWHs,nUWDs,n
   ð2Þ
where Ps,n is the population of Korea in 2010 by sex and
age group; Morbs,n is the morbidity rate by sex and age group;
UWHs,n is the utility weight for healthy controls by sex and age
group; UWDs,n is the utility weight for diseased people by sex
and age group; n is the age group in 5-year intervals: 1 (20–24), 2
(25–29) … 12 (75–79), 13 (Z80); and s is sex: 1 (men) and
2 (women).
Similarly, QALY loss due to mortality is equal to the sum of
individual QALY losses due to mortality (Equation 3) and can be
regarded as the total loss of life expectancy and a reﬂection of
HRQOL (Equation 4). Utility weight averages over 10-year inter-
vals were used as the utility weights for each age group. We
assumed that the life expectancy of the median age was repre-
sentative of each age group. For the last age group (Z90 years),
however, we used the life expectancy value for those who were
92 years old. Life expectancy was based on the general population
—rather than healthy control—because it is hard to determine
the life expectancies of healthy controls. We introduced the term
“αs,m” to adjust life expectancy by sex and age group when
calculating QALY loss due to mortality. This correction value
was used to ﬁne-tune the life expectancy at the start and end of
the age group on the basis of the assumption of age linearity
adjustment [16].
QALY lossmortality¼ ∑
2
s¼1
∑
15
n0 ¼1
Qs,n0 Morts,n0
  ð3Þ
Qs,n0 ¼ ∑
7
m¼1
UWHs,m,n0  LEs,m,n0 þαs,m
   ð4Þ
Qs,n0 is the representative QALY loss due to mortality by
sex and age group; Morts,n0 is the number of disease-speciﬁc
deaths in Korea in 2010 by sex and age group; UWHs,m,n0 is
the utility weight for healthy control by sex and age group;
LEs,m,n0 is the life expectancy by sex and age group; αs,m is
the correction value for life expectancy by sex and age group;
n0 is the age group in 5-year intervals: 1 (20–24), 2 (25–29) … 14
(85–89), 15 (Z90); m is the age group in 10-year intervals: 1 (20–
29), 2 (30–39) … 6 (70–79), 7 (Z80); and s is sex: 1 (men) and 2
(women).
Predicted QALY Loss through to 2040
Future changes in QALY loss were also investigated. We
replaced the population size of 2010 with the future population
projections for 2015-2040 (at 5-year intervals) to calculate
QALY loss. Future population projection data reﬂect changes
in the population structure by age and include three main
scenarios: low, middle, and high estimates. These scenarios
were determined by considering variable factors, such as birth
rate, mortality, and international migration. We assumed that
other factors that would affect the estimated QALY loss values,
such as mortality and utility weight, would stay at the same
levels determined for 2010. SPSS (version 19.0) software was
used for all statistical analyses. This study was approved by
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0047-0001).Results
A total of 229,229 respondents participated in the KCHS 2010,
including 104,575 men (45.6%) and 124,654 women (54.4%). There
were 112,439 (49.1%) respondents who reported having 1 or more
of the 13 NCDs. Appendix Table 1 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2014.09.008 provides the
number of respondents who reported NCDs according to sex and
age. In men, the most common morbidity was hypertension
(20.2%), followed by diabetes mellitus (8.5%) and hyperlipidemia
(8.2%). In women, the most common morbidity was hypertension
(22.4%), followed by arthritis (19.5%) and osteoporosis (13.0%).
The utility weights for the 13 diseases by sex and age group
are shown in Figure 1 A,B. As the age of the respondents
increased, the utility weights for each disease tended to decrease.
In some cases, however, the utility weights did not decrease as
age increased. For example, in men with osteoporosis, the utility
weight at age 20 to 24 years (0.7907) was lower than that at age 30
to 39 years (0.9208); in women with myocardial infarction, the
utility weight at age 40 to 49 years (0.8331) was lower than that at
age 50 to 59 years (0.8670).Fig. 1 – Utility weights for 13 noncommunicable diseaseAll utility weights for each disease according to age group
were lower than those of similarly aged healthy controls, except
women aged between 20 and 29 years with myocardial infarction.
Differences in utility weights between healthy controls and
diseased people tended to increase with age. In men with stroke,
the difference in utility weights between age 20 and 29 years was
0.0867, but for men 80 years or older was 0.3374. In addition, in
women with depression, the difference in utility weights at age
20 to 29 years was 0.0822, but among women 80 years or older
was 0.3461.
Among the 13 investigated NCDs, the largest total QALY loss
was for hypertension (513,113 QALYs; units omitted hereafter; see
Appendix Table 2 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2014.09.008). The next largest total QALY
loss was for arthritis (509,317), followed by stroke (431,049) and
diabetes mellitus (337,424). Estimates of QALY loss by sex are
shown in Figure 2. In men, the largest total QALY loss was for
stroke (219,923), followed by hypertension (155,254) and diabetes
mellitus (144,515). In women, the largest total QALY loss was for
arthritis (415,957), followed by hypertension (357,859) and osteo-
porosis (261,246). QALY loss due to mortality was largest due to
stroke among men (159,715), followed by myocardial infarction
(76,880) and diabetes mellitus (73,272). QALY loss due to mortality
was largest for stroke among women (147,018), followed by
diabetes mellitus (57,925) and myocardial infarction (42,672).s in (A) men and (B) women according to age group.
Fig. 2 – QALY loss due to morbidity and mortality according to sex and disease. DM, diabetes mellitus; HTN, hypertension; MI,
myocardial infarction; QALY, quality-adjusted life-year.
F
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among men (139,565), followed by arthritis (91,921) and diabetes
mellitus (71,244). QALY loss due to morbidity was largest for
arthritis among women (410,592), followed by hypertension
(333,378) and osteoporosis (257,174).
According to future population projections by the Korean
Statistical Information Service, the population of Korea will
increase through 2040 (according to the high estimate) (Fig. 3),
and the total population in 2040 will be 57,147,183. According to
the middle estimate, the Korean population will peak in 2030,
with a total population of 51,091,352 in 2040. According to the
lowest estimate, the Korean population will decline after 2015 to
a total population of 45,167,201 by 2040.
When these three estimates were used as substitutes for 2010
population, the total QALY loss demonstrated a continual
increase through to 2040 in all cases (Fig. 3). When the middle
estimate of the future Korean population was applied, theig. 3 – Predicting QALY loss due to the main noncommunicable
ypertension; MI, myocardial infarction; QALY, quality-adjusteddifference in the total QALY loss between 2010 and 2040 was
greatest for hypertension (840,582), followed by stroke (719,076)
and diabetes mellitus (474,607). In terms of increase in ratio,
however, asthma was greatest (2.82 times bigger than 2010),
followed by stroke (2.67 times) and hypertension (2.64 times).Discussion
This study was performed to estimate QALY loss in Korean adults
according to 13 NCDs in 2010 and predict changes in future QALY
loss through to 2040. In 2010, the largest total QALY loss was due
to hypertension, followed by arthritis, stroke, and diabetes
mellitus. Furthermore, it is expected that the QALY loss due to
NCDs will continue to grow by 2040 given the future population
projections.diseases, 2010-2040. DM, diabetes mellitus; HTN,
life-year.
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sex and age group. The most frequently used HRQOL instrument
for calculating QALY is the EQ-5D [17], but there are concerns
about the ability of the EQ-5D to discriminate the HRQOL of
health states [18]. This limitation, however, might be mainly
limited to mild health states [19], and so it may not be a major
problem in this study because we primarily focused on major
NCDs, which will further decrease the HRQOL in comparison with
mild diseases. Furthermore, the use of the EQ-5D is also a
concern, in that it is considered a problematic outcome measure
of psychotic disorders [20]. Although there is a study that reports
the EQ-5D as suitable for calculating QALY in patients with
anxiety disorders [21], QALY loss due to depression may have
been underestimated in this study.
By reviewing the utility weights for 13 NCDs according to sex
and age, we found that in some cases the utility weights of the
respondents did not decrease as age increased. For example, the
utility weight of women aged 20 to 29 years with myocardial
infarction was higher than that of healthy controls aged between
20 and 29 years. These results might be due to the characteristics
of the disease—which is very rare in young people—because only
two women respondents aged between 20 and 29 years devel-
oped myocardial infarction.
Because the total QALY loss is the sum of QALY losses due to
morbidity and mortality, the 13 NCDs included in this study could
be divided into two groups according to the composition of QALY
loss. For example, in the case of atopic dermatitis and allergic
rhinitis, there was no QALY loss due to mortality. Likewise, NCDs
that mainly affect QALY loss due to morbidity include cataract,
hyperlipidemia, and depression. Myocardial infarction and
stroke, however, largely affect QALY loss due to mortality. To
reduce the QALY loss due to each disease, it is necessary to
consider the composition of QALY loss and, in particular, assess
the needs of people with a range of disorders that mainly cause
disability [22].
Among the 13 assessed NCDs, the burden of hypertension
was greatest with respect to QALY loss, followed by arthritis,
stroke, and diabetes mellitus. Similar to the results of a previous
study [13], these results were mainly attributed to high preva-
lence among Koreans, although the utility weight for hyper-
tension was not especially low compared with those of other
NCDs. The next largest total QALY loss in this study was for
arthritis; in particular, the largest QALY loss due to morbidity
was also for arthritis. These results are similar to those of a
previous study in which arthrosis of the hip and knee was on
top on the annual QALY loss using the EQ-5D [12]. Arthritis, of
which osteoarthritis is the most common type, affects quality of
life through various health dimensions, such as physical activity
and pain, and is associated with other risk factors for chronic
diseases [23]. In terms of QALY loss due to mortality, stroke was
the most important. These results are similar to those of
another study that reported QALE loss due to stroke as the
highest among ﬁve major NCDs [13]. Furthermore, stroke dem-
onstrated not only the largest DALY but also the greatest years
of life lost in Korea in 1990 and 2010 [24]. Therefore, establishing
interventions that reduce the stroke burden are urgently
required.
It might be meaningful to compare these results with the
ﬁndings of Korea from the Global Burden of Disease 2010 study
[24]. First, in terms of mortality, these two estimates are generally
similar because they are based on the same vital registration
data. Differences, however, might be due to disease classiﬁcation
between the two estimates and reﬂect the HRQOL values of
healthy control used to calculate QALY loss [25]. Second, in terms
of morbidity, the ranks of depression and diabetes mellitus were
relatively higher for DALY than for QALY loss, whereas those of
stroke and cataract were relatively higher in terms of QALY overDALY. These discrepancies might result from the difference in
the valuation methods and target populations used to elicit
utility and disability weights [26,27]. Because cultural difference
can affect valuation tasks [28], local country-speciﬁc HRQOL data
might be more appropriate than disability weights when estimat-
ing QALY loss to morbidity.
When applying the three future population estimates, total
QALY loss due to the 13 NCDs continued to increase through to
2040 in all cases. These results were mostly attributed to population
aging, although given that the low population estimate will decline
after 2015, the total QALY loss according to the low population
estimate will also continue to increase through to 2040. NCDs will
predominate in an aging society, and susceptibility to NCDs also
increases due to aging [29]. Therefore, given the problem of the
aging Korean population [30], the health care system of Korea will
need to address the needs of elderly with NCDs.
This study has several limitations. First, not all NCDs were
included in this study. For example, cancer, a classic NCD, was
omitted. This is because the KCHS 2010 did not collect data on
cancer-related morbidity. Second, the possible effects of comor-
bidities were not considered when calculating QALY loss. Esti-
mates of QALY loss will change according to the manner of
dealing with comorbidities, such as by combining utility weight
with various combinations of NCDs. Third, we considered only
the future population projections when predicting changes in
QALY losses. If there are changes in the values of other factors
that would affect QALY loss, such as mortality and morbidity
rates and utility weight, the value of future QALY loss will also
change.Conclusions
In terms of total QALY loss, arthritis, hypertension, stroke, and
diabetes mellitus are the most important NCDs. It is expected
that QALY loss due to NCDs will continue to grow given the
future population projection. Policymakers could develop cost-
effective interventions to reduce disease burden by examining
the estimates of QALY loss presented in this study.
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